ClinicalTrials.gg
Drug

NBI 77860 clinical trials

Also written GSK561679.

studies test it
9
open now
0
in phase 3
0
first study started
2006

How each study uses NBI 77860 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

CRF1 antagonist
2

Development codes

GSK561679
5
NBI-77860
1

Other names

Verucerfont
1

Studies by the year they started

9 studies that test it; most in 2007 (3)

Studies that test NBI 77860, by start year
YearStudies
20061
20073
20081
20091
20102
20151

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 6 · Other 3

GlaxoSmithKline (5) · VA Office of Research and Development (1) · Emory University (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · Neurocrine Biosciences (1)

Often tested with

Tested in the same studies.

GW 876008 (2)

Studies

Open first, then newest update. How each study uses NBI 77860 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9